STRS Ohio’s C4 Therapeutics CCCC Stock Holding History

STRS Ohio’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5,600	Closed	-$17K	–	1963
2023 Q1	$17K	Hold	5,600	–	–	﹤0.01%	1878
2022 Q4	$33K	Hold	5,600	–	–	﹤0.01%	1844
2022 Q3	$49K	Hold	5,600	–	–	﹤0.01%	1832
2022 Q2	$42K	Hold	5,600	–	–	﹤0.01%	1879
2022 Q1	$135K	Hold	5,600	–	–	﹤0.01%	1790
2021 Q4	$180K	Hold	5,600	–	–	﹤0.01%	1760
2021 Q3	$250K	Hold	5,600	–	–	﹤0.01%	1710
2021 Q2	$211K	Sell	5,600 -8,700	-61%	-$312K	﹤0.01%	1801
2021 Q1	$528K	Buy	14,300 +11,700	+450%	+$465K	﹤0.01%	1549
2020 Q4	$86K	Buy	+2,600	New	+$75.4K	﹤0.01%	1918

Other funds holding CCCC

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

STRS Ohio's CCCC Position: Q2 2023 in Review

STRS Ohio sold out of C4 Therapeutics (CCCC) in Q2 2023, closing a stake of 5,600 shares — an estimated $17K sold.

STRS Ohio first reported a position in CCCC in Q4 2020 and held it in 10 quarters. The position peaked at $528K in Q1 2021. 100 funds tracked by Wall St. Rank hold CCCC as of Q2 2023.

STRS Ohio reported no remaining C4 Therapeutics position as of Q2 2023 after selling out during the quarter.
STRS Ohio sold 5,600 C4 Therapeutics shares in Q2 2023, an estimated $17K.
STRS Ohio first reported a position in C4 Therapeutics in Q4 2020 and held it in 10 quarters.
STRS Ohio's C4 Therapeutics position peaked at $528K in Q1 2021.
100 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2023.

Based on STRS Ohio's 13F filing for Q2 2023, filed 31 Jul 2023.